Literature DB >> 17459052

Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells.

Yasuo Shinoda1, Ken-Ichi Kozaki, Issei Imoto, Wataru Obara, Hitoshi Tsuda, Yoichi Mizutani, Taro Shuin, Tomoaki Fujioka, Tsuneharu Miki, Johji Inazawa.   

Abstract

Array-based comparative genomic hybridization (array-CGH) has powerful potential for high-throughput identification of genetic aberrations in cell genomes. We identified high-level amplification of kallikrein (KLK) genes, which are mapped to 19q13.3 and belong to the serine protease family, in the course of a program to screen a panel of urinary bladder carcinoma cell lines for genomic copy number aberrations using our in-house CGH-array. Expression levels of KLK5, -6, -8 and -9 were significantly increased in three cell lines with copy number gains of these KLK genes. Knockdown of these KLK transcripts by specific small interfering RNA significantly inhibited the invasion of a bladder carcinoma cell line through Matrigel in vitro. Reverse transcription-polymerase chain reaction analysis of 42 primary bladder tumor samples showed that increased expression of KLK5 was frequently observed in invasive tumors (pT2-pT4) (14.3%, 6/42) compared with superficial tumors (pTa, pT1) (0%, 0/42; P = 0.0052), and expression levels of KLK5, -6, -8 and -9 mRNA were higher in invasive tumors than in superficial tumors (P < 0.0001, P = 0.0043, P = 0.0790 and P = 0.0037, respectively). These observations indicate that KLK5, -6, -8 and -9 may be the most likely targets of the 19q13.3 amplification, and may play a crucial role in promoting cancer-cell invasion in bladder tumor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459052     DOI: 10.1111/j.1349-7006.2007.00495.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  13 in total

1.  Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.

Authors:  Theodoros Tokas; Margaritis Avgeris; Christos Alamanis; Andreas Scorilas; Konstantinos G Stravodimos; Constantinos A Constantinides
Journal:  J Cancer Res Clin Oncol       Date:  2016-11-17       Impact factor: 4.553

2.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

3.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

4.  Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.

Authors:  Jane Bayani; Miltiadis Paliouras; Chris Planque; Shannon J C Shan; Cassandra Graham; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2008-07-22       Impact factor: 6.603

5.  Effect of Productive Human Papillomavirus 16 Infection on Global Gene Expression in Cervical Epithelium.

Authors:  Sa Do Kang; Sreejata Chatterjee; Samina Alam; Anna C Salzberg; Janice Milici; Sjoerd H van der Burg; Craig Meyers
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

6.  Identification and validation of genes involved in cervical tumourigenesis.

Authors:  Thangarajan Rajkumar; Kesavan Sabitha; Neelakantan Vijayalakshmi; Sundersingh Shirley; Mayil Vahanan Bose; Gopisetty Gopal; Ganesharaja Selvaluxmy
Journal:  BMC Cancer       Date:  2011-02-22       Impact factor: 4.430

7.  LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.

Authors:  R Matsuda; H Enokida; T Chiyomaru; N Kikkawa; T Sugimoto; K Kawakami; S Tatarano; H Yoshino; K Toki; Y Uchida; K Kawahara; K Nishiyama; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

8.  Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.

Authors:  Margaritis Avgeris; Georgia Papachristopoulou; Athanasios Polychronis; Andreas Scorilas
Journal:  Clin Proteomics       Date:  2011-05-31       Impact factor: 3.988

9.  Protein-binding microarray analysis of tumor suppressor AP2α target gene specificity.

Authors:  Jan Kerschgens; Stéphanie Renaud; Frédéric Schütz; Luigino Grasso; Tanja Egener-Kuhn; Jean-François Delaloye; Hans-Anton Lehr; Horst Vogel; Nicolas Mermod
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

10.  Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment.

Authors:  Stefanie Krenzer; Heike Peterziel; Cornelia Mauch; Sachiko I Blaber; Michael Blaber; Peter Angel; Jochen Hess
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.